Clinical Trials Logo

Prurigo clinical trials

View clinical trials related to Prurigo.

Filter by:

NCT ID: NCT04183335 Completed - Neurodermatitis Clinical Trials

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)

Start date: December 12, 2019
Phase: Phase 3
Study type: Interventional

Primary Objective: To demonstrate the efficacy of dupilumab on itch response in participants with prurigo nodularis (PN), inadequately controlled on topical prescription therapies or when those therapies are not advisable. Secondary Objectives: To demonstrate the efficacy of dupilumab on additional itch endpoints in participants with PN, inadequately controlled on topical prescription therapies or when those therapies are not advisable. To demonstrate efficacy of dupilumab on skin lesions of PN. To demonstrate the improvement in health-related quality of life. To evaluate safety outcome measures. To evaluate immunogenicity of dupilumab.

NCT ID: NCT03816891 Completed - Prurigo Nodularis Clinical Trials

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

Start date: March 11, 2019
Phase: Phase 2
Study type: Interventional

Study of the efficacy, safety, tolerability, pharmacokinetics (PK), and immunogenicity of Vixarelimab (KPL-716) in subjects with prurigo nodularis.

NCT ID: NCT03677401 Completed - Pruritus Clinical Trials

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Start date: August 29, 2018
Phase: Phase 3
Study type: Interventional

Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis

NCT ID: NCT03630198 Completed - Plaque Psoriasis Clinical Trials

Pain Outcomes Following Intralesional Corticosteroid Injections

Start date: October 1, 2018
Phase: Phase 4
Study type: Interventional

Corticosteroid therapy, including intralesional and topical applications, has many indications within the fields of Dermatology, Plastic Surgery, and Orthopedics. However, these injections can be quite painful, which leads many patients to discontinue treatment. Often, the injection involves a mixture of local anesthetic and corticosteroids despite a lack of evidence that the use of lidocaine improves pain. Due to the acidic pH, the lidocaine component of the injection can actually cause a significant burning sensation during the procedure. Lidocaine does not have anti-inflammatory properties and does not treat the underlying pathology. By including another medication, lidocaine also adds cost and risk to the procedure. The purpose of this study is to see if removing lidocaine from intralesional injections decreases the pain of injection.

NCT ID: NCT03576287 Recruiting - Prurigo Nodularis Clinical Trials

Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis

Start date: July 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the anti-pruritic effect of apremilast in patients with known PN.

NCT ID: NCT03546816 Completed - Pruritus Clinical Trials

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Start date: May 2, 2018
Phase: Phase 3
Study type: Interventional

Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis

NCT ID: NCT03540160 Terminated - Psoriasis Clinical Trials

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

Start date: March 15, 2018
Phase: Phase 3
Study type: Interventional

Study of the long term safety of serlopitant for the treatment of pruritus in adults.

NCT ID: NCT03497975 Completed - Prurigo Nodularis Clinical Trials

PRISM Study-Pruritus Relief Through Itch Scratch Modulation

PRISM
Start date: August 7, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

To investigate the anti-pruritic efficacy and safety of Nalbuphine Extended Release (ER) (NAL ER) tablets in Prurigo Nodularis. Subjects will be randomized to NAL ER (or matching placebo) with the primary endpoint evaluation at Week 14. During the open label extension, subjects who received NAL ER will continue on NAL ER and subjects who received placebo will crossover to NAL ER.

NCT ID: NCT03340155 Recruiting - Psoriasis Clinical Trials

Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases

BioUV2017
Start date: October 30, 2017
Phase: N/A
Study type: Interventional

The molecular mechanisms of action of photo(chemo)therapy in skin diseases are investigated in this study. The phototherapeutic modalities employed include UVB (ultraviolet B), UVA (ultraviolet A), PUVA (psoralen+UVA) and/or extracorporeal photochemotherapy (photopheresis). The study will address whether and how photo(chemo)therapy affects specific biologic pathways in different skin disorders and search for predictive biomarkers.

NCT ID: NCT03181503 Completed - Prurigo Nodularis Clinical Trials

Safety and Efficacy of Nemolizumab in PN

Start date: October 2, 2017
Phase: Phase 2
Study type: Interventional

The aim of this study is to assess the safety and efficacy of nemolizumab in subjects with prurigo nodularis.